Benzinga | Dec 9, 2020 08:05AM EST

INOVIO Announces VGX-3100 Phase 2 Efficacy Results In Treatment Of Precancerous Anal Dysplasia Caused By HPV-16/18; Says Showed Resolution Of HPV-16/18-Associated Precancerous Anal Lesions In 50% Of Subjects Six Months Following Start Of Treatment

PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy results demonstrating that DNA medicine VGX-3100, the company's lead immunotherapy asset, showed resolution of HPV-16/18-associated precancerous anal lesions (HSIL) in 50% (11 of 22) of subjects six months following the start of treatment. The open label, single arm trial also showed VGX-3100 to be safe and well-tolerated in treating men and women with HPV-16-/18-associated anal dysplasia. INOVIO plans to pursue a registrational Phase 3 clinical trial for HPV-16-/18-associated anal dysplasia as well as to apply for rare and orphan disease designation for this indication in 2021.

Dr. C?line Bouchard, Gynecologist and Anoscopist at Centre M?dical Sant? Femme in Qu?bec City, Canada and Coordinating Principal Investigator for the Phase 2 trial, said, "Results of this trial are very promising and may offer a safe and efficacious new therapeutic option for patients suffering from this debilitating condition."